BASSER CENTER FOR BRCA – PENN MEDICINE

So wonderful to read through the BASSER Progress report! Gives me such hope for our children’s future. IN 10 YEARS By 2030, Basser will continue to improve our understanding of BRCA, allowing us to overcome chemotherapy resistance, develop new targeted therapies for mutation carriers, and have better medications for managing metastatic breast cancer. We also…

Details

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Abstract BACKGROUND Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation–associated early breast cancer. METHODS We conducted a phase 3, double-blind, randomized trial involving patients with human epidermal growth factor receptor 2 (HER2)–negative early…

Details

Study: Patient outcomes and experiences of going flat

Study: Patient outcomes and experiences of going flat Summary: Some patients with early-stage breast cancer or those considering risk-reducing surgery may choose mastectomy without reconstruction. This is often referred to as “going flat.” The results of this study suggest that surgeons play a significant role in supporting a patient’s decision to go flat. (3/23/2021) Relevance:…

Details

Genetic testing could prevent future health risk for those with family history of cancer

By Madison Pitsch Published: Oct. 20, 2020 at 5:11 PM EDT https://www.1011now.com/2020/10/20/albion-mother-gets-genetic-testing-for-cancer-encourages-others-at-risk-to-do-so/ LINCOLN, Neb. (KOLN) -October is Breast Cancer Awareness Month. For those who are facing a family history of cancer diagnoses, there is a way to learn more about your own risks for cancer. Genetic testing, for people at high risk of cancer, can change the…

Details

BRCA1 cancer CRISPR disease & medicine genetics & genomics News

The researchers catalogued 3,893 variants of the gene implicated in cancer using CRISPR. Sukanya Charuchandra Nearly 4,000 genetic variants of BRCA1, a tumor-suppressing gene whose loss of function can lead to breast and ovarian cancer, have been functionally classified, according to a study published September 12 in Nature. These findings could help with ascribing cancer risk to…

Details